#USA #Cambridge #CAR-T therapy #RiboX #RXIM002

RiboX Therapeutics Hits a Milestone with RXIM002

In a groundbreaking achievement, RiboX Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its Investigational New Drug (IND) application for RXIM002. This remarkable therapy emerges as the first circular RNA-based in vivo CAR therapy, marking a pivotal moment in the field of biotechnology focused on autoimmune diseases.

RiboX, based in Shanghai and Cambridge, has positioned itself at the forefront of clinical-stage biotechnology with its commitment to pioneering fully engineered circular RNA (circRNA) therapeutics. RXIM002 is being developed to treat autoimmune cytopenias, a category of disorders characterized by a reduction in blood cell counts caused by erroneous immune responses.

RXIM002 utilizes a targeted lipid nanoparticle (tLNP) delivery system designed to transport circRNA that encodes a chimeric antigen receptor (CAR) targeting CD19. The innovative aspect of this therapy lies in its ability to generate functional CAR-T cells directly within a patient's body through in vivo processes as opposed to traditional ex vivo methods. This breakthrough has the potential to enhance patient accessibility to CAR-T treatments, which have previously been viewed as complex and costly.

With RXIM002, patients may experience profound B cell depletion, leading to an immune reset and drug-free remission—an appealing prospect for individuals with chronic autoimmune conditions. The recent IND approval comes after successful initial trials conducted in China, which provided safety and preliminary efficacy data on the therapy.

Interestingly, the FDA's prompt approval allows RiboX to initiate its Phase 1 clinical trial, titled POPULUS-1, which is set to explore RXIM002's safety and early efficacy in individuals suffering from relapsed or refractory autoimmune cytopenias, particularly immune thrombocytopenia (ITP). This disease, characterized by decreased platelet counts, puts patients at a heightened risk of bruising and bleeding, necessitating innovative treatment solutions.

The enhanced development plan noted by RiboX incorporates findings from prior investigator-initiated trials, which explored the therapeutic impact of RXIM002 on autoimmune diseases, leading to insights that strengthen the drug’s profile.

RiboX Therapeutics' CEO, Dr. Weiyi Zhang, expressed the significance of this achievement:

"The FDA IND clearance for RXIM002 is a pivotal milestone for RiboX and for the field of circRNA medicines. As the first-in-class circRNA in vivo CAR-T therapy to enter the clinic, RXIM002 exemplifies our ability to translate robust pre-clinical results and rigorous early clinical evidence into an accelerated development path."

This momentum reinforces RiboX’s dedication to establishing itself as a leader in the precision RNA therapeutics sector, focusing on diverse therapeutic needs across multiple regions. The company's proprietary platforms adaptively respond to the unmet clinical needs of patients globally, enhancing therapeutic avenues in autoimmune diseases and beyond.

As RXIM002 paves its way through clinical trials, the industry eagerly anticipates the potential this transformative therapy holds for patients battling autoimmune cytopenias. RiboX Technologies remains committed to the innovation and advancement of RNA-based solutions as it aims to change the treatment landscape in immunotherapy, offering hope where conventional treatments may fall short.

In conclusion, the FDA's approval of RXIM002 is not just a success for RiboX but also a beacon of hope for patients seeking effective therapies for autoimmune disorders. With its in vivo capabilities, this innovation could reshape the future of CAR-T therapies and related approaches, potentially providing a new path toward sustained health and wellness for many.

For more information, please visit RiboX Technologies.